Affiliations 

  • 1 Department of Clinical Genetics, Leiden University Medical Centre, Leiden, The Netherlands
  • 2 Result Laboratorium, Amphia Hospital, Breda, The Netherlands
  • 3 Franciscus Gasthuis & Vlietland Rotterdam, Rotterdam, The Netherlands
  • 4 Laboratoire National de Santé, National Center of Genetics, Dudelange, Luxembourg
Hemoglobin, 2025 Mar 30.
PMID: 40159794 DOI: 10.1080/03630269.2025.2484230

Abstract

Beta (β) thalassemia is an inherited disorder that occurs following mutations or deletions in the β globin gene. Rarely, it is caused by variants in genes coding for erythroid transcriptional factors or trans-acting factors. Here, we report three novel variants of SUPT5H revealed by next generation sequencing. This, gene has been progressively acknowledged as a mimicker of β thalassemia trait in two independent individuals and one family. These individuals have the same features, including hypochromic microcytic indices, increased Hb A2 levels, without mutations in the β globin gene. The three novel SUPT5H variants identified in this study (c.1168_1169del, c.2688del and c.307+1G>A) are frameshift variants leading to a premature stop codon or an intronic variant predicted to alter the splice site consensus sequence by in silico software. All three variants are characterized as Loss-of-Function variants either by generating a truncated protein or haplo-insufficiency due to nonsense-mediated decay. These findings confirm the general observation that most variants in SUPT5H associated with a β thalassemia trait phenotype are Loss-of-Function variants. This gene should be considered as a potential target gene in the genetic diagnosis of any unsolved cases of increased HbA2 and unexplained inconsistency of phenotype and genotype of β thalassemia intermedia.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.